RxDoctor Payments DataLook up a doctor →

Breanna Byrd

Nurse Practitioner · Baton Rouge, LANPI 1750853198

Payments from drug & device makers

$9,436in general payments, 2019–2025

Across 414 payments — averaging $22.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$767
  • Novartis$598
  • AstraZeneca$581
  • Merck$472
  • Daiichi Sankyo Inc.$438
  • Takeda Pharmaceuticals U.S.A., Inc.$430
  • plus $6K from 49 others

What the payments were for

  • Food & beverage$8,84794%
  • Education$5896%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,436 in reported general payments places this provider in the 95th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Medicare billing

Part B allowed, 2024
$43,580
Medicare patients
77
Services billed
909

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib13$186,419
XareltoRivaroxaban36$39,277
EliquisApixaban35$27,596
Pantoprazole Sodium18$1,121
Hydroxyurea35$890
Exemestane12$810
Oxycodone Hcl38$750
Tramadol Hcl28$644
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen35$546
Prednisone85$507
Anastrozole31$507
Letrozole27$498
Dexamethasone18$447
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst18$383
Potassium Chloride28$377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$270$214,01548 claims
Johnson & JohnsonXarelto$767$39,27736 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 969 nurse practitioner providers in Louisiana.

Other nurse practitioner in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →